Jennison Associates
VRTX icon

Jennison Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Jennison Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,000
Closed -$6.45M – 726
2021
Q1 		$6.45M Buy
+30,000
New +$6.59M ﹤0.01% 456
2014
Q3 		– Sell
-450,000
Closed -$42.6M – 756
2014
Q2 		$42.6M Buy
+450,000
New +$31.6M 0.04% 354

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates's VRTX Position: Q1 2026 in Review

Jennison Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, selling an estimated $238M and leaving 2,740,059 shares worth $1.22B. The position accounts for 0.84% of the portfolio, ranked #29.

Jennison Associates first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.74B in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Jennison Associates held 2,740,059 shares of Vertex Pharmaceuticals worth $1.22B as of Q1 2026.
  • Jennison Associates sold 509,482 Vertex Pharmaceuticals shares in Q1 2026, an estimated $238M.
  • Vertex Pharmaceuticals made up 0.84% of Jennison Associates's portfolio in Q1 2026, its #29 holding.
  • Jennison Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Jennison Associates's Vertex Pharmaceuticals position peaked at $2.74B in Q2 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.